Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Moderna, Inc. (MRNA)

213.86 +5.89 (+2.83%)
As of 10:28:53 AM EDT. Market Open.
Trade Moderna on Coinbase
Chart Range Bar
Loading chart for MRNA

What's happening with MRNA?

13m ago
Powered by Yahoo Scout

Moderna’s recent news centers on positive Phase 3 melanoma-vaccine results with Merck, alongside investor concerns about valuation, manufacturing complexity, and falling COVID-vaccine revenue. The company also received regulatory progress for seasonal vaccines and continues developing oncology and respiratory products.

Powered by Yahoo Scout
  • Previous Close 207.97
  • Open 203.97
  • Bid 206.53 x 100
  • Ask 227.12 x 100
  • Day's Range 202.62 - 218.16
  • 52 Week Range 22.28 - 254.48
  • Volume 4,390,123
  • Avg. Volume 21,055,931
  • Market Cap (intraday) 85.381B
  • Beta (5Y Monthly) 1.10
  • PE Ratio (TTM) --
  • EPS (TTM) -7.98
  • Earnings Date Nov 6, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 138.37
  • Morningstar Rating Rating available with Stock Picks access

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

www.modernatx.com

4,700

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/28/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

MRNA
625.70%
S&P 500 (^GSPC)
12.98%

1-Year Return

MRNA
744.22%
S&P 500 (^GSPC)
12.24%

3-Year Return

MRNA
197.61%
S&P 500 (^GSPC)
87.85%

5-Year Return

MRNA
38.49%
S&P 500 (^GSPC)
68.27%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 145M
Earnings -782M
Profit Margin -539.31%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-1B
-500M
0
500M
1B
-500.0%
-400.0%
-300.0%
-200.0%
-100.0%

Analyst Insights

View More

Analyst Price Targets

45.00 Low
138.37 Average
213.86 Current
251.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/27/2026
Analyst William Blair
Rating Action Downgrade
Rating Market Perform
Price Action --
Price Target --

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -141.43%

  • Return on Assets (ttm)

    -13.26%

  • Return on Equity (ttm)

    -39.00%

  • Revenue (ttm)

    2.23B

  • Net Income Avi to Common (ttm)

    -3.15B

  • Diluted EPS (ttm)

    -7.98

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.14B

  • Total Debt/Equity (mrq)

    19.04%

  • Levered Free Cash Flow (ttm)

    299.25M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: